Moffitt Advancing Preemptive PGx Testing Effort to Optimize Treatment for Patients Receiving Chemo | GenomeWeb

NEW YORK (GenomeWeb) – Moffitt Cancer Center is advancing a program to preemptively test patients scheduled to go on chemotherapy for pharmacogenetic markers that impair their ability to metabolize and respond well to nausea, vomiting, and pain medications.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.